Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio para evaluar la adherencia a apalutamida en participantes con cáncer de próstata metastásico sensible a hormonas en Francia (OBSAPA)

2 de noviembre de 2026 actualizado por: Janssen Cilag S.A.S.

Un estudio observacional prospectivo en Francia: Adherencia a APAlutamida en pacientes con cáncer de próstata metastásico sensible a hormonas (mHSPC) en Francia

This study aims to explore the real-world treatment adherence, persistence of apalutamide, and assess the risk of non-adherence according to the participant's profile and behavior of metastatic hormone-sensitive prostate cancer (mHSPC) participants treated with apalutamide during the first year of continued treatment.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Tipo de estudio

De observación

Inscripción (Estimado)

540

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • Caen, Francia, 14076
        • Reclutamiento
        • Centre Francois Baclesse

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Masculino

Método de muestreo

Muestra no probabilística

Población de estudio

Adult male (according to their chromosomal composition at birth) participants with confirmed diagnosis of mHSPC will be enrolled at the time of initiation of treatment with apalutamide.

Descripción

Inclusion criteria:

  • Male (based on chromosomal composition at birth) and aged greater than or equal to (>=) 18 years.
  • Must have a histologically or cytologically confirmed diagnosis of prostate adenocarcinoma
  • Must have documented metastatic hormone-sensitive prostate cancer (mHSPC)
  • Must have agreed with the treating physician to initiate treatment with apalutamide (plus androgen-deprivation therapy [ADT]) in accordance with the current product characteristics summary, based on the physician's decision, prior to study inclusion
  • Able to understand the content of the patient information sheet and has provided oral consent for data collection. Has received the information sheet and has not objected to data collection
  • Must have a baseline prostate-specific antigen (PSA) level collected prior to the first administration of apalutamide.
  • Must agree to complete adherence and quality-of-life questionnaires during the study, including before the first administration of apalutamide

Exclusion criteria:

  • Has already received or is currently receiving apalutamide, or any other androgen receptor pathway inhibitor (ARPI; including but not limited to abiraterone acetate, darolutamide, and enzalutamide) or chemotherapy for mHSPC
  • Has received an investigational drug (including vaccines) or used an invasive investigational medical device within 90 days prior to study start or data collection
  • Is currently receiving active treatment for prostate cancer as part of an interventional study
  • Has received ADT for mHSPC for more than 4 months prior to starting apalutamide treatment
  • Has experienced progression under ADT (and thus became castration-resistant) before starting apalutamide treatment
  • Beneficiary of State Medical Aid [AME]
  • Does not speak/read French
  • Under guardianship or curatorship
  • Under judicial protection

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Metastatic hormone-sensitive prostate cancer (mHSPC): Routine Clinical Practice Setting

Participants with confirmed diagnosis of mHSPC will be enrolled at the time of initiation of treatment with apalutamide (Month 0) in routine clinical practice and will be followed up until 12 months after end of study visit (Month 12). No intervention will be administered as a part of this study.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of Participants With Adherence to Apalutamide at 12 Months
Periodo de tiempo: At 12 months

Adherent participants are defined as participants adherent to apalutamide at every visit until 12 months according to the Medication Adherence Report Scale (MARS-5). MARS-5 is a well-known participant-reported adherence measure (PRAM) consisting of 5 items assessing the adherence behavior of a participant to a given medication with a 5-point scale, ranging from "always" to "never" (1-5 points). The scale total ranges from 5 (lowest adherence) to 25 points (maximal adherence). A higher score indicates more adherence.

At 12 months
Number of Participants Reporting Change in Adherence According to MARS-5 by Apalutamide Formulation
Periodo de tiempo: At 12 months

Participants with changes in adherence according to the MARS-5, by apalutamide formulation will be reported. MARS-5 is a well-known PRAM consisting of 5 items assessing the adherence behavior of a participant to a given medication with a 5-point scale, ranging from "always" to "never" (1-5 points). The scale total ranges from 5 (lowest adherence) to 25 points (maximal adherence). A higher score indicates more adherence.

At 12 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Clinical Risk Factor Among Adherent and Non-adherent Participants: ECOG Status
Periodo de tiempo: Up to 12 months

Clinical risk factors for treatment the Eastern Cooperative Oncology Group (ECOG) will be reported.

Up to 12 months
Clinical Risk Factor Among Adherent and Non-adherent Participants: Comorbidities
Periodo de tiempo: Up to 12 months

Clinical risk factors for treatment prostate comorbidities will be reported.

Up to 12 months
Clinical Factors of Adherence at 12 Months: Disease Volume
Periodo de tiempo: At 12 months

Predictive clinical factors of adherence that is disease volume at 12 months will be reported.

At 12 months
Percentage of Adherent Participants at 3, 6, and 9 Months
Periodo de tiempo: At 3,6,9 months

Percentage of adherent participants at 3 months, 6 months and 9 months according to the MARS-5 will be reported. MARS-5 is a well-known PRAM consisting of 5 items assessing the adherence behavior of a participant to a given medication. Participants are asked to evaluate how often they adopt each behavior with a 5-point scale, ranging from "always" to "never" (1-5 points). The scale total ranges from 5 (lowest adherence) to 25 points (maximal adherence). A higher score indicates more adherence.

At 3,6,9 months
Number of Participants Reporting Change in Adherence According to MARS-5 by Apalutamide Formulation at 3, 6 and 9 Months
Periodo de tiempo: At 3, 6 and 9 months

Participants with changes in adherence according to the MARS-5, by apalutamide formulation will be reported. MARS-5 is a well-known PRAM consisting of 5 items assessing the adherence behavior of a participant to a given medication with a 5-point scale, ranging from "always" to "never" (1-5 points). The scale total ranges from 5 (lowest adherence) to 25 points (maximal adherence). A higher score indicates more adherence.

At 3, 6 and 9 months
Number of Participants with Risk of Non-Adherence as per Social, Psychological, Usage and Rational (SPUR) Factors as per SPUR Adherence Tool
Periodo de tiempo: Baseline, Months 3, 6, 9 and 12

SPUR is a validated, participant-reported questionnaire that assesses adherence-related behavior across thirteen specific behavioral drivers categorized into four dimensions: Social, Psychological, Usage, and Rational. It consists of 24 items and uses a 5-point Likert scale for each item (ranging from "strongly disagree" to "strongly agree"), with some items reverse-coded to minimize response bias. Scores are calculated for each behavioral driver dimension and score indicating the risk of non-adherence is calculated from them, allowing assessment of global non-adherence risk as well as analysis of the behavioral constituents of that risk by considering the mix of drivers present and their relative importance. Here, higher scores indicate more adherence.

Baseline, Months 3, 6, 9 and 12
Spearman Correlation Coefficients at Baseline and Month 12
Periodo de tiempo: At Baseline and Month 12

Spearman correlation coefficients between each of the 13 behavioral drivers will be reported.

At Baseline and Month 12
SPUR Global Risk Score at Baseline and Month 12
Periodo de tiempo: At Baseline and Month 12

SPUR is a validated, participant-reported questionnaire that assesses adherence-related behavior across thirteen specific behavioral drivers categorized into four dimensions: Social, Psychological, Usage, and Rational. It consists of 24 items and uses a 5-point Likert scale for each item (ranging from "strongly disagree" to "strongly agree"), with some items reverse-coded to minimize response bias. Scores are calculated for each behavioral driver dimension and score indicating the risk of non-adherence is calculated from them, allowing assessment of global non-adherence risk as well as analysis of the behavioral constituents of that risk by considering the mix of drivers present and their relative importance. Here, higher scores indicate more adherence.

At Baseline and Month 12
Functional Assessment of Cancer Therapy- Prostate (FACT-P) Score
Periodo de tiempo: At Baseline, Months 3, 6, 9, 12

The FACT-P questionnaire is used to assess quality of life (QoL) in men undergoing therapy for prostate cancer. It is composed of 39 items using a 5-point Likert-like scale. Each item is rated on a 0 to 4, and then combined to produce subscale scores, as well as a global QoL score. Higher scores represent better QoL.

At Baseline, Months 3, 6, 9, 12
Change from Baseline in FACT-P Score at 3, 6 and 9 Months
Periodo de tiempo: Baseline, Months 3, 6, 9, 12

The FACT-P questionnaire is used to assess quality of life in men undergoing therapy for prostate cancer. It is composed of 39 items using a 5-point Likert-like scale. Each item is rated on a 0 to 4 , and then combined to produce subscale scores, as well as a global QoL score. Higher scores represent better QoL.

Baseline, Months 3, 6, 9, 12
Demographics Characteristics of Participants: Age
Periodo de tiempo: Baseline

The demographic characteristics of participants that is, age will be reported.

Baseline
Demographics Characteristics of Participants: Socio-Professional Category
Periodo de tiempo: Baseline

The demographic characteristics of participants that is, socio-professional category (the participant's last occupation held prior to retirement: Managerial [higher managerial or lower managerial], Non-managerial [intermediate or small employers or lower supervisory or semi-routine or routine], Never worked or long-term unemployed will be reported.

Baseline
Demographics Characteristics of Participants: G8 Geriatric Screening Score
Periodo de tiempo: Baseline

The demographic characteristics of participants that is, G8 geriatric screening score will be reported. The G8 consists of eight items: participant age (greater than [>]85, 80-85, less than [<]80), and seven items from the original 18-item MNA (Mini Nutritional Assessment: appetite changes, weight loss, mobility, neuropsychological problems, body mass index, medication, and self-rated health). The total score ranges from 0 to 17, with higher scores indicating a lower risk of impairments.

Baseline
Prostate-Specific Antigen (PSA) Level at Androgen-Deprivation Therapy (ADT) Initiation
Periodo de tiempo: Up to 12 months

PSA levels at ADT initiation will be reported.

Up to 12 months
PSA Level at Baseline
Periodo de tiempo: At Baseline

PSA levels at baseline will be reported.

At Baseline
Change from Baseline in PSA Levels
Periodo de tiempo: Baseline up to 12 months

Change from baseline in PSA levels will be reported.

Baseline up to 12 months
Serum Testosterone at Baseline
Periodo de tiempo: At baseline

Serum testosterone levels will be reported.

At baseline
Time from Initial Diagnosis of Prostate Cancer to Metastatic Stage
Periodo de tiempo: Baseline up to 12 months

Time from initial diagnosis of prostate cancer to metastatic stage for metachronous participants will be reported.

Baseline up to 12 months
Type of Imaging Methods Used for Cancer Diagnostics
Periodo de tiempo: Baseline

Number of participants with different type of imaging methods used for cancer diagnostic (for example, magnetic resonance imaging [MRI], Prostate Specific Membrane Antigen Positron Emission Tomography [PSMA-PET], Positron emission tomography [PET] choline, Computed Tomography scan [CT scan], bone scan) will be reported.

Baseline
Osteodensitometry Score
Periodo de tiempo: Baseline

Osteodensitometry score, a type of imaging method used for cancer diagnostic will be reported.

Baseline
Tumor assessment: Location of Metastases
Periodo de tiempo: Baseline

Location of metastases as assessed by bone and CT/MRI scans, PSMA-PET scans and any other imaging methods documented in routine practice will be recorded.

Baseline
Tumor assessment: Number of Lesions
Periodo de tiempo: Baseline

Number of lesions as assessed by bone and CT/MRI scans, PSMA-PET scans and any other imaging methods documented in routine practice will be recorded.

Baseline
ECOG Performance Status
Periodo de tiempo: At Baseline

ECOG is a 5-point scale, where 0=Fully active, 1=Ambulatory, carry out work of sedentary nature, 2=Ambulatory, capable of all self-care, 3=Capable of limited self-care, confined to bed or chair more than 50% of waking hours, 4=Completely disabled, no self-care, totally confined to bed or chair, 5=Dead.

At Baseline
Number of Participants with History of Treatment for Prostate Cancer
Periodo de tiempo: Baseline

Participants with history of treatment for prostate cancer will be reported.

Baseline
Number of Participants Reporting Concomitant Diseases
Periodo de tiempo: Baseline

Participants with Current concomitant diseases (co-morbidities) will be reported.

Baseline
Number of Participants With Vital Sign Assessments
Periodo de tiempo: Baseline

Participants with relevant vital sign assessment (blood pressure and pulse) will be reported.

Baseline
Time from Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Diagnosis to Treatment Initiation
Periodo de tiempo: Baseline up to 12 months

Time from mHSPC diagnosis to treatment initiation is defined as the time between date of mHSPC diagnosis and first administration of apalutamide.

Baseline up to 12 months
Percentage of Participants Reaching Undetectable PSA
Periodo de tiempo: At Months 3,6,9,12

Percentage of participants with undetectable PSA levels that is PSA level less than or equal to (<=) 0.2 nanogram per milliliter (ng/mL) will be reported.

At Months 3,6,9,12
Percentage of Participants Reaching Ultralow (UL) PSA
Periodo de tiempo: At Months 3,6,9,12

Percentage of participants with ultralow PSA levels that is PSA level <= 0.02 ng/mL will be reported.

At Months 3,6,9,12
Time to Undetectable PSA
Periodo de tiempo: Up to 12 months

Time to undetectable PSA is defined as the time between first administration of apalutamide and date of undetectable PSA.

Up to 12 months
Time to UL PSA
Periodo de tiempo: Up to 12 months

Time to UL PSA is defined as the time between first administration of apalutamide and date of UL PSA.

Up to 12 months
Number of Participants with Greater Than or Equal to (>=) 50% Decline in PSA Values (PSA 50) from Baseline
Periodo de tiempo: Baseline up to 12 months

Participants with >=50% reduction in PSA value from baseline will be reported.

Baseline up to 12 months
Number of Participants with >= 90% Decline in PSA Values (PSA 90) from Baseline
Periodo de tiempo: Baseline up to 12 months

Participants with >=90% reduction in PSA value from baseline will be reported.

Baseline up to 12 months
Number of Participants with Decrease in PSA Levels (PSA Halving-time)
Periodo de tiempo: Up to 12 months

Participants with decrease in PSA levels (PSA halving-time) over time will be reported.

Up to 12 months
Progression-Free Survival (PFS)
Periodo de tiempo: At Months 3,6,9,12

PFS is defined as the time from initiation of apalutamide until earliest record of disease progression determined by physician's assessment, or death.

At Months 3,6,9,12
Number of Deaths
Periodo de tiempo: At Months 3,6,9,12

The number of deaths at months 3,6,9 and 12 will be reported.

At Months 3,6,9,12
Number of Participants Reporting Change Since Baseline in Apalutamide and ADT Modalities
Periodo de tiempo: At Baseline, Months 3,6,9,12

Participants reporting changes since baseline in Apalutamide and ADT Modalities (that is, dose, route of administration, number of tablets, time of intake) will be reported.

At Baseline, Months 3,6,9,12
Time from mHSPC Diagnosis to ADT Treatment Initiation
Periodo de tiempo: Baseline up to Month 12

Time from mHSPC diagnosis to ADT treatment initiation will be reported.

Baseline up to Month 12
Time Between ADT and Apalutamide Treatment Initiation
Periodo de tiempo: Baseline up to Month 12

Time between ADT and apalutamide initiation will be reported.

Baseline up to Month 12
Number of Participants with Apalutamide Treatment Discontinuation
Periodo de tiempo: At Months 3,6,9,12

Participants who have discontinued apalutamide treatment will be reported.

At Months 3,6,9,12
Reasons for Discontinuation of Apalutamide Treatment
Periodo de tiempo: At Months 3,6,9,12

Participants who have discontinued apalutamide treatment and the reasons for discontinuation will be reported.

At Months 3,6,9,12
Time to Discontinuation of Apalutamide Treatment
Periodo de tiempo: At Months 3,6,9,12

Time to discontinuation of apalutamide treatment will be reported.

At Months 3,6,9,12
Number of Participants Receiving Planned Subsequent Treatment for Prostate Cancer
Periodo de tiempo: At Months 3,6,9,12

Participants receiving planned subsequent treatment for prostate cancer will be reported.

At Months 3,6,9,12
Percentage of Participants who Consulted for Treatment
Periodo de tiempo: At Months 3,6,9,12

The percentage of participants who consulted for treatment will be reported.

At Months 3,6,9,12
Percentage of Participants who Used Caregiver Support
Periodo de tiempo: At Months 3,6,9,12

Percentage of participants who use caregiver support will be reported.

At Months 3,6,9,12
Number of Participants Receiving Concomitant Treatments
Periodo de tiempo: At Baseline, Months 3,6,9,12

Participants receiving concomitant treatments will be reported.

At Baseline, Months 3,6,9,12
Number of Participants with a Change in Concomitant Treatments
Periodo de tiempo: At Months 3,6,9,12

Participants with a change in concomitant treatments will be reported.

At Months 3,6,9,12
Number of Participants Experiencing At Least One Adverse Event (AE)
Periodo de tiempo: At Months 3,6,9,12

An adverse event is any untoward medical occurrence in a participant administered a medicinal product. An adverse event does not necessarily have a causal relationship with the treatment. A serious adverse event is any untoward medical occurrence that at any dose: Results in death, Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect, Is a suspected transmission of any infectious agent via a medicinal product or is medically important. Severity of AEs will be graded as follows: Mild (Easily tolerated symptoms), Moderate (Sufficient discomfort, causes interference with normal activity) and Severe (Extreme distress).

At Months 3,6,9,12
Percentage of Undetectable PSA According to Adherence Levels
Periodo de tiempo: At Months 3,6,9,12

Percentage of undetectable PSA according to adherence levels, that is PSA level <= 0.2 ng/mL will be reported.

At Months 3,6,9,12
Percentage of UL PSA According to Adherence Levels
Periodo de tiempo: At Months 3,6,9,12

Percentage of UL PSA according to adherence levels, that is PSA level <= 0.02 ng/mL will be reported.

At Months 3,6,9,12
Number of Participants with PSA 50 Response According to Adherence Levels
Periodo de tiempo: At Months 3,6,9, and 12

Participants with >=50% reduction in PSA value from baseline according to adherence levels will be reported.

At Months 3,6,9, and 12
Number of Participants with PSA 90 Response According to Adherence Levels
Periodo de tiempo: At Months 3,6,9, and 12

Participants with >=90% reduction in PSA value from baseline according to adherence levels will be reported.

At Months 3,6,9, and 12
Clinical Risk Factor Among Adherent and Non-adherent Participants: Number of Participants Reporting the Use of Concomitant Treatments
Periodo de tiempo: Up to 12 months

Participants using the concomitant treatments will be reported.

Up to 12 months
Clinical Risk Factor Among Adherent and Non-adherent Participants: Prostate Specific Antigen (PSA) Rate
Periodo de tiempo: Up to 12 months

Clinical risk factors for prostate specific antigen (PSA) rate will be reported.

Up to 12 months
Clinical Risk Factor Among Adherent and Non-adherent Participants: Number of Participants Reporting the Socio-professional Category
Periodo de tiempo: Up to 12 months

Participants with socio-professional category will be reported.

Up to 12 months
Clinical Risk Factor Among Adherent and Non-adherent Participants: Number of Participants Reporting the Use of Disease Specialized Consultations
Periodo de tiempo: Up to 12 months

Participants reporting the use of disease specialized consultations will be reported.

Up to 12 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Janssen-Cilag France Clinical Trial, Janssen-Cilag France

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

18 de diciembre de 2025

Finalización primaria (Estimado)

3 de enero de 2028

Finalización del estudio (Estimado)

18 de septiembre de 2028

Fechas de registro del estudio

Enviado por primera vez

26 de enero de 2026

Primero enviado que cumplió con los criterios de control de calidad

4 de marzo de 2026

Publicado por primera vez (Actual)

5 de marzo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

3 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Palabras clave

Otros números de identificación del estudio

  • 56021927MPC4009

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .